Allschwil, Switzerland – September 17, 2024
See the original post:
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
Ad hoc announcement pursuant to Art. 53 LR
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Fairway Consulting Group (FCG), a leading executive search firm focused on providing outstanding talent solutions for the pharmaceutical, biotechnology, diagnostic, and medical device industries, announced today the appointment of Brennan Clark as Vice President of Executive Search.
Read the rest here:
Fairway Consulting Group Appoints Brennan Clark as Vice President of Executive Search
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure’s oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance.
See original here:
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall,...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in which the independent directors have provided their resignation from the Board, effective immediately:
The rest is here:
Independent Directors of 23andMe Resign from Board
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces that it has closed its initial public offering of 1,550,000 shares of common stock at an offering price of $4.00 per share. The gross proceeds to the Company from the offering were $6,200,000, before deducting underwriting discounts and commissions and other offering expenses. The Company’s common stock began trading on the NYSE American LLC on September 16, 2024 under the symbol “KAPA.”
See the article here:
Kairos Pharma Closing of $6.2 Million Initial Public Offering
MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV® (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company’s contract manufacturer’s facility following an inspection by the US Food and Drug Administration (FDA), as well as the FDA review timeline to resume distribution of the product.
More:
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the eighteen-month anniversary of the initial issuance date or 60 days following the date the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the five-year anniversary of the initial issuance date or six months following the date the Company publicly announces the entry into one or more agreements relating to the further development and commercialization for AM-401 or AM-411, provided at least one such agreement covers a territory that includes all or a part of the European Union or the United States. The closing of the offering is expected to occur on or about September 19, 2024, subject to the satisfaction of customary closing conditions.
Continue reading here:
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
To potentially include adolescents and antibody persistence up to two years